News and Trends 14 Mar 2023 Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion. Seagen is a global biotechnology company that discovers, develops and commercializes cancer medicines. The boards of directors of both companies have unanimously approved the transaction. “Pfizer is deploying its financial resources to […] March 14, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2023 Sanofi adds diabetes drug through Provention Bio $2.9B acquisition Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. The transaction adds […] March 13, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Expert Advice 2 Mar 2023 5 steps to strategic partnerships for healthtech startups By Varvara Melikhova, founder and CEO of Unison Innovations Strategic partnerships are a better way to build a product’s capabilities than outright acquisitions. While the M&A path is set out for the most mature successful startups, early-stage partnerships can enhance a product’s market value and provide access to Big Pharma expertise and infrastructure, which significantly […] March 2, 2023 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2023 GC Biopharma acquiring hemophilia rare disease pipeline GC Biopharma Corp., a South Korean provider of biopharmaceutical products, has signed an asset purchase agreement with Catalyst Biosciences to acquire three programs related to the orphan hematology disorders. The agreement includes Marzeptacog alfa (MarzAA), an engineered factor VIIa, which is ready for phase 3 clinical stage development. In its previous clinical development trials, MarzAA […] February 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Feb 2023 Crown Bioscience acquiring Indivumed’s service business and biobank Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH. A share purchase agreement (SPA) between was executed in December, 2022, and subject to customary closing adjustments, the transaction is expected to close in April 2023. Indivumed […] February 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Five key trends shaping life sciences in 2023 By Kevin Wayer, president – government, education, infrastructure and life sciences industries, JLL, and Travis McCready, head of life sciences, industries Americas, JLL After an unprecedented period of growth during the pandemic, life sciences activity normalized in 2022. The life sciences industry has not been immune to the macroeconomic challenges plaguing the global economy, but […] January 11, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Clinical trends for 2023 By Richard Staines, account director, Optimum Strategic Communications Few would deny that the decade has had a turbulent start, but after the tragedies of the COVID-19 pandemic and the Ukraine war, there’s hope that 2023 will see a new wave of clinical research. Exciting new technologies such as gene editing, gene therapy and a next […] January 11, 2023 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 What’s in store for biotech in 2023? Perhaps 2022 will best be remembered in the life science industry for the return of many of the face-to-face events that fell by the wayside during the COVID-19 pandemic. It might have been a mixed year for biotech companies, but 2023 is a new year, with new challenges, but also new opportunities. So what do […] January 11, 2023 - 14 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 Ensoma acquiring Twelve Bio Arix Bioscience, a global venture capital company focused on investing in breakthrough biotechnology companies, announced that portfolio company Twelve Bio will be acquired by Ensoma in connection with an $85 million financing of Ensoma which Arix co-led, investing $9 million. Twelve Bio is a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas medicines. […] January 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2023 Blacksmith Medicines merging with Forge Therapeutics Blacksmith Medicines, Inc., and Forge Therapeutics have signed a definitive merger agreement. This will create a biopharma company dedicated to discovering and developing medicines targeting a large class of proteins called metalloenzymes. The initial focus will be on oncology and infection. “We are excited to unveil the merger of Blacksmith and Forge, which we believe […] January 3, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2022 Prenetics acquires ACT Genomics Prenetics Global Limited is acquiring a majority stake in ACT Genomics Holdings Company Limited, an Asia based genomics company specializing in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand and in the U.K. “With the addition of ACT’s technologies, capabilities and team, Prenetics will be well-positioned to accelerate the utilization of genetic […] December 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 Polyplus announces completion of acquisition of Xpress Biologics to expand plasmid DNA Polyplus has announced the completion of an acquisition of Belgian Xpress Biologics to expand plasmid DNA technology. Xpress Biologics specializes in the production of plasmid DNA and protein using microbial expression systems. Polypus concentrates on the manufacturing of advanced therapeutic medicinal products from research to commercial grade. The acquisition will strategically expand the Polyplus plasmid […] December 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email